# Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)

> **NCT01953601** · PHASE3 · TERMINATED · sponsor: **Merck Sharp & Dohme LLC** · enrollment: 1454 (actual)

## Conditions studied

- Amnestic Mild Cognitive Impairment
- Alzheimer's Disease
- Prodromal Alzheimer's Disease

## Interventions

- **DRUG:** Verubecestat 12 mg (Parts 1 and 2)
- **DRUG:** Verubecestat 40 mg (Parts 1 and 2)
- **OTHER:** Placebo (Part 1)

## Key facts

- **NCT ID:** NCT01953601
- **Lead sponsor:** Merck Sharp & Dohme LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2013-11-05
- **Primary completion:** 2018-04-17
- **Final completion:** 2018-04-17
- **Target enrollment:** 1454 (ACTUAL)
- **Last updated:** 2019-05-17


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01953601

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01953601, "Efficacy and Safety Trial of Verubecestat (MK-8931) in Participants With Prodromal Alzheimer's Disease (MK-8931-019)". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT01953601. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*